LINK-001
Kidney Disease (Acute Kidney Injury)
Phase 2Active
Key Facts
About LinkGevity
LinkGevity is a private, preclinical-stage biotech pioneering an AI-driven approach to longevity drug discovery. The company's proprietary 'Blueprint Theory' of aging informs its AI platform, which analyzes biomedical data to map biological triggers and identify novel therapeutic targets. Its lead asset class, Anti-Necrotics™, aims to inhibit necrosis (uncontrolled cell death) and is being advanced into Phase 2 trials for kidney disease and aging, with additional applications in tissue engineering and organ preservation. The company blends deep scientific expertise with a platform designed to systematically generate new drug candidates for healthspan extension.
View full company profile